Annual FCF
-$5.21 M
+$4.62 M+47.03%
31 December 2022
Summary:
Nymox Pharmaceutical annual free cash flow is currently -$5.21 million, with the most recent change of +$4.62 million (+47.03%) on 31 December 2022. During the last 3 years, it has risen by +$4.84 million (+48.21%).NYMX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$991.00 K
+$258.00 K+20.66%
31 March 2023
Summary:
Nymox Pharmaceutical quarterly free cash flow is currently -$991.00 thousand, with the most recent change of +$258.00 thousand (+20.66%) on 31 March 2023.NYMX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$1.99 M
+$3.22 M+61.79%
31 March 2023
Summary:
Nymox Pharmaceutical TTM free cash flow is currently -$1.99 million, with the most recent change of +$3.22 million (+61.79%) on 31 March 2023.NYMX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NYMX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +48.2% | +67.0% | +78.5% |
| 5 y5 years | +33.6% | +47.6% | +72.9% |
NYMX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -166.3% | -108.4% | -125.3% |
Nymox Pharmaceutical Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$991.00 K(-20.7%) | -$1.99 M(-61.8%) |
| Dec 2022 | -$5.21 M(-47.0%) | -$1.25 M(-4.4%) | -$5.21 M(-16.2%) |
| Sept 2022 | - | -$1.31 M(-183.9%) | -$6.21 M(-21.4%) |
| June 2022 | - | $1.56 M(-137.0%) | -$7.90 M(-30.4%) |
| Mar 2022 | - | -$4.21 M(+86.7%) | -$11.36 M(+15.6%) |
| Dec 2021 | -$9.83 M(-2.2%) | -$2.25 M(-24.9%) | -$9.83 M(+6.0%) |
| Sept 2021 | - | -$3.00 M(+57.7%) | -$9.27 M(-9.9%) |
| June 2021 | - | -$1.90 M(-28.8%) | -$10.29 M(-2.5%) |
| Mar 2021 | - | -$2.67 M(+57.5%) | -$10.55 M(+5.0%) |
| Dec 2020 | -$10.05 M(+35.3%) | -$1.70 M(-57.8%) | -$10.05 M(-1.2%) |
| Sept 2020 | - | -$4.02 M(+85.8%) | -$10.17 M(+26.5%) |
| June 2020 | - | -$2.16 M(-0.2%) | -$8.04 M(+0.4%) |
| Mar 2020 | - | -$2.17 M(+19.6%) | -$8.01 M(+7.8%) |
| Dec 2019 | -$7.43 M(-5.2%) | -$1.81 M(-4.2%) | -$7.43 M(+1.4%) |
| Sept 2019 | - | -$1.89 M(-11.3%) | -$7.33 M(-6.3%) |
| June 2019 | - | -$2.13 M(+33.8%) | -$7.82 M(+2.9%) |
| Mar 2019 | - | -$1.59 M(-7.0%) | -$7.60 M(-3.1%) |
| Dec 2018 | -$7.84 M(+26.3%) | -$1.71 M(-28.1%) | -$7.84 M(+6.0%) |
| Sept 2018 | - | -$2.38 M(+24.7%) | -$7.39 M(-0.6%) |
| June 2018 | - | -$1.91 M(+4.2%) | -$7.44 M(+1.9%) |
| Mar 2018 | - | -$1.83 M(+44.4%) | -$7.30 M(+17.6%) |
| Dec 2017 | -$6.21 M(+37.8%) | -$1.27 M(-47.7%) | -$6.21 M(-3.9%) |
| Sept 2017 | - | -$2.43 M(+37.3%) | -$6.45 M(+37.9%) |
| June 2017 | - | -$1.77 M(+139.1%) | -$4.68 M(+30.0%) |
| Mar 2017 | - | -$740.00 K(-51.2%) | -$3.60 M(-20.1%) |
| Dec 2016 | -$4.50 M(+20.0%) | -$1.52 M(+132.3%) | -$4.50 M(+6.3%) |
| Sept 2016 | - | -$653.30 K(-5.0%) | -$4.24 M(-11.1%) |
| June 2016 | - | -$687.60 K(-58.2%) | -$4.76 M(-4.4%) |
| Mar 2016 | - | -$1.64 M(+31.3%) | -$4.99 M(+32.8%) |
| Dec 2015 | -$3.75 M(-32.0%) | -$1.25 M(+5.9%) | -$3.75 M(+3.5%) |
| Sept 2015 | - | -$1.18 M(+30.1%) | -$3.62 M(-10.3%) |
| June 2015 | - | -$908.20 K(+121.0%) | -$4.04 M(-10.9%) |
| Mar 2015 | - | -$411.00 K(-63.4%) | -$4.54 M(-17.8%) |
| Dec 2014 | -$5.52 M(-17.9%) | -$1.12 M(-29.6%) | -$5.52 M(-6.3%) |
| Sept 2014 | - | -$1.60 M(+13.7%) | -$5.89 M(-5.6%) |
| June 2014 | - | -$1.40 M(+0.8%) | -$6.24 M(-3.5%) |
| Mar 2014 | - | -$1.39 M(-6.9%) | -$6.47 M(-3.8%) |
| Dec 2013 | -$6.72 M(-19.1%) | -$1.50 M(-23.0%) | -$6.72 M(-6.5%) |
| Sept 2013 | - | -$1.94 M(+19.2%) | -$7.19 M(+4.2%) |
| June 2013 | - | -$1.63 M(-1.1%) | -$6.90 M(-5.1%) |
| Mar 2013 | - | -$1.65 M(-16.0%) | -$7.27 M(-12.5%) |
| Dec 2012 | -$8.31 M(-18.2%) | -$1.96 M(+18.7%) | -$8.31 M(+0.8%) |
| Sept 2012 | - | -$1.65 M(-17.2%) | -$8.24 M(-4.6%) |
| June 2012 | - | -$2.00 M(-25.7%) | -$8.64 M(-4.2%) |
| Mar 2012 | - | -$2.69 M(+41.9%) | -$9.01 M(-11.3%) |
| Dec 2011 | -$10.16 M(-229.4%) | -$1.90 M(-7.5%) | -$10.16 M(-392.8%) |
| Sept 2011 | - | -$2.05 M(-13.7%) | $3.47 M(-18.0%) |
| June 2011 | - | -$2.38 M(-38.1%) | $4.23 M(-22.0%) |
| Mar 2011 | - | -$3.84 M(-132.7%) | $5.42 M(-30.9%) |
| Dec 2010 | $7.85 M | $11.73 M(-1009.1%) | $7.85 M(-261.2%) |
| Sept 2010 | - | -$1.29 M(+9.2%) | -$4.87 M(+5.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | -$1.18 M(-16.1%) | -$4.63 M(+7.4%) |
| Mar 2010 | - | -$1.41 M(+42.6%) | -$4.31 M(+22.8%) |
| Dec 2009 | -$3.51 M(-0.0%) | -$988.80 K(-5.4%) | -$3.51 M(+3.4%) |
| Sept 2009 | - | -$1.05 M(+21.2%) | -$3.39 M(+3.8%) |
| June 2009 | - | -$862.90 K(+41.6%) | -$3.27 M(+5.6%) |
| Mar 2009 | - | -$609.60 K(-30.2%) | -$3.10 M(-11.7%) |
| Dec 2008 | -$3.51 M(-28.1%) | -$873.50 K(-5.3%) | -$3.51 M(-1.4%) |
| Sept 2008 | - | -$922.00 K(+33.5%) | -$3.56 M(-0.4%) |
| June 2008 | - | -$690.50 K(-32.4%) | -$3.57 M(-23.2%) |
| Mar 2008 | - | -$1.02 M(+10.8%) | -$4.65 M(-4.7%) |
| Dec 2007 | -$4.88 M(+6.3%) | -$922.40 K(-1.4%) | -$4.88 M(-6.0%) |
| Sept 2007 | - | -$935.30 K(-47.1%) | -$5.19 M(+8.2%) |
| June 2007 | - | -$1.77 M(+41.5%) | -$4.79 M(-2.9%) |
| Mar 2007 | - | -$1.25 M(+1.4%) | -$4.93 M(+7.6%) |
| Dec 2006 | -$4.59 M(+48.2%) | -$1.23 M(+127.7%) | -$4.59 M(+15.0%) |
| Sept 2006 | - | -$541.50 K(-71.6%) | -$3.99 M(-5.5%) |
| June 2006 | - | -$1.91 M(+111.4%) | -$4.22 M(+30.5%) |
| Mar 2006 | - | -$903.10 K(+42.1%) | -$3.23 M(+4.5%) |
| Dec 2005 | -$3.09 M(-15.0%) | -$635.40 K(-17.8%) | -$3.09 M(-2.6%) |
| Sept 2005 | - | -$772.90 K(-16.2%) | -$3.18 M(-6.0%) |
| June 2005 | - | -$922.50 K(+20.8%) | -$3.38 M(+11.2%) |
| Mar 2005 | - | -$763.50 K(+6.2%) | -$3.04 M(-16.5%) |
| Dec 2004 | -$3.64 M(-6.3%) | -$719.00 K(-26.4%) | -$3.64 M(-9.2%) |
| Sept 2004 | - | -$976.30 K(+68.1%) | -$4.01 M(+9.1%) |
| June 2004 | - | -$580.80 K(-57.4%) | -$3.67 M(-10.0%) |
| Mar 2004 | - | -$1.36 M(+25.4%) | -$4.08 M(+5.0%) |
| Dec 2003 | -$3.89 M(+60.6%) | -$1.09 M(+69.6%) | -$3.89 M(+30.8%) |
| Sept 2003 | - | -$640.70 K(-35.3%) | -$2.97 M(-6.8%) |
| June 2003 | - | -$990.20 K(-15.2%) | -$3.19 M(+8.5%) |
| Mar 2003 | - | -$1.17 M(+579.8%) | -$2.94 M(+21.5%) |
| Dec 2002 | -$2.42 M(-17.6%) | -$171.80 K(-80.0%) | -$2.42 M(-22.1%) |
| Sept 2002 | - | -$857.30 K(+15.6%) | -$3.10 M(+4.5%) |
| June 2002 | - | -$741.60 K(+14.3%) | -$2.97 M(+3.5%) |
| Mar 2002 | - | -$648.80 K(-24.3%) | -$2.87 M(-2.2%) |
| Dec 2001 | -$2.94 M(-30.8%) | -$857.00 K(+18.3%) | -$2.94 M(-1.0%) |
| Sept 2001 | - | -$724.60 K(+12.9%) | -$2.96 M(-12.7%) |
| June 2001 | - | -$641.60 K(-10.0%) | -$3.40 M(-15.2%) |
| Mar 2001 | - | -$712.70 K(-19.5%) | -$4.00 M(-5.6%) |
| Dec 2000 | -$4.24 M(+51.2%) | -$885.70 K(-23.3%) | -$4.24 M(+12.7%) |
| Sept 2000 | - | -$1.16 M(-7.5%) | -$3.76 M(+4.2%) |
| June 2000 | - | -$1.25 M(+31.5%) | -$3.61 M(+18.2%) |
| Mar 2000 | - | -$950.10 K(+133.2%) | -$3.06 M(+8.9%) |
| Dec 1999 | -$2.81 M(-48.2%) | -$407.50 K(-59.5%) | -$2.81 M(-30.0%) |
| Sept 1999 | - | -$1.01 M(+45.1%) | -$4.01 M(-4.8%) |
| June 1999 | - | -$692.70 K(-1.1%) | -$4.21 M(+2.2%) |
| Mar 1999 | - | -$700.20 K(-56.6%) | -$4.12 M(-23.9%) |
| Dec 1998 | -$5.42 M(+50.7%) | -$1.61 M(+33.5%) | -$5.42 M(+42.3%) |
| Sept 1998 | - | -$1.21 M(+100.3%) | -$3.81 M(+46.4%) |
| June 1998 | - | -$603.00 K(-69.8%) | -$2.60 M(+30.2%) |
| Mar 1998 | - | -$2.00 M | -$2.00 M |
| Dec 1997 | -$3.60 M | - | - |
FAQ
- What is Nymox Pharmaceutical annual free cash flow?
- What is the all time high annual FCF for Nymox Pharmaceutical?
- What is Nymox Pharmaceutical quarterly free cash flow?
- What is the all time high quarterly FCF for Nymox Pharmaceutical?
- What is Nymox Pharmaceutical TTM free cash flow?
- What is the all time high TTM FCF for Nymox Pharmaceutical?
What is Nymox Pharmaceutical annual free cash flow?
The current annual FCF of NYMX is -$5.21 M
What is the all time high annual FCF for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high annual free cash flow is $7.85 M
What is Nymox Pharmaceutical quarterly free cash flow?
The current quarterly FCF of NYMX is -$991.00 K
What is the all time high quarterly FCF for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high quarterly free cash flow is $11.73 M
What is Nymox Pharmaceutical TTM free cash flow?
The current TTM FCF of NYMX is -$1.99 M
What is the all time high TTM FCF for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high TTM free cash flow is $7.85 M